66 filings
8-K
ACRV
Acrivon Therapeutics Inc
14 May 24
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
8:00am
10-Q
2024 Q1
ACRV
Acrivon Therapeutics Inc
Quarterly report
14 May 24
7:31am
EFFECT
ACRV
Acrivon Therapeutics Inc
30 Apr 24
Notice of effectiveness
12:15am
ARS
2023 FY
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Annual report to shareholders
8:36am
DEFA14A
ACRV
Acrivon Therapeutics Inc
26 Apr 24
Additional proxy soliciting materials
8:33am
8-K
hvl xfxgwcb3g4n9ehke
24 Apr 24
Results of Operations and Financial Condition
4:01pm
8-K
ls8q0s55gjl
9 Apr 24
Acrivon Therapeutics Announces $130 Million Private Placement Financing
7:05am
S-8
aqzre yao8jcjhi2wy3
29 Mar 24
Registration of securities for employees
9:06am
8-K
8z13n7jvrc2h59b3mr
28 Mar 24
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
8:00am
8-K
jg2fxivgt q04svqgu
4 Mar 24
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
8:15am
8-K
7ql9ktb39iajyl495g
8 Feb 24
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
8:27am
8-K
uqax8yqi2d6c8mnce
8 Jan 24
Regulation FD Disclosure
7:28am
EFFECT
11xp5 bn5lm2vsqv
18 Dec 23
Notice of effectiveness
12:15am
CORRESP
x4bci6wag8jwxt
12 Dec 23
Correspondence with SEC
12:00am
8-K
xqy8 ffb3ntg
8 Dec 23
Entry into a Material Definitive Agreement
4:21pm
UPLOAD
jwmtp23 1f1m0fq3x
5 Dec 23
Letter from SEC
12:00am
S-3
s5xey3xh8
1 Dec 23
Shelf registration
4:35pm